Posts Tagged ‘Disease Patients’

UK Studies to Look at Alzheimer’s, Down Syndrome

Monday, July 12th, 2010

The University of Kentucky Sanders-Brown Center on Aging is looking for two groups of patients to help learn more about Alzheimer’s disease.

One study will examine how a new drug can supplement existing treatment; the other focuses on Down syndrome and Alzheimer’s.

The first study is looking at how the drug Dimebon can help Alzheimer’s patients already taking Aricept.

Because Alzheimer’s is a complex disease, patients sometimes need multiple drugs to address their symptoms, said Dr. Gregory Jicha, assistant professor of neurology at the UK College of Medicine. Aricept is one of the most widely prescribed Alzheimer’s drugs in the country.

Dimebon is thought to improve the mitochondrial function in brain cells, preventing damage. Cell parts called mitochondria are critical to brain function because they are the primary source of cells’ energy.

Aricept appears to enhance the brain’s concentration of acetylcholine, an enzyme crucial to memory and learning, he said.

Jicha said a good candidate for this study would have relatively mild symptoms. “In the early stage of the disease people can understand what the trial means and participate in the decision to help find better medicine and potential cures for Alzheimer’s,” he said.

The UK effort is part of an international project that will evaluate more than 1,000 patients, including at least a dozen at UK.

Another new research project looks at the connection between Down syndrome and Alzheimer’s. The $2.4 million, five-year study will look at how Down syndrome and Alzheimer’s disease may affect a person’s memory and thinking as they get older, said Dr. Elizabeth Head, who will lead the study.

The study will recruit and follow 40 people older than 35 with Down syndrome. In addition, 10 to 12 people with Down syndrome and Alzheimer’s disease will be recruited for a single research session.

The Down syndrome patients without Alzheimer’s will be tested every six months.

Head said the life expectancy of Down syndrome patients has increased dramatically over the years but the services they need as they age have not kept up. “There is really not a whole lot out there for them,” she said. “They are a little underserved.”

At the same time, she said, Down syndrome patients offer a unique opportunity to study Alzheimer’s. The chromosomal abnormality that creates Down syndrome also results in the overproduction of the protein that causes Alzheimer’s.

“They make a protein that causes Alzheimer’s disease. They are making too much of it from birth,” she said.

Most middle-age Down syndrome patients have full-blown Alzheimer’s disease in their brain but not all of them develop dementia, she said. Understanding how they continue to function could be key to helping others with Alzheimer’s, she said.

More than 400,000 people in the United States have Down syndrome. Overall, 50 percent of people with Down syndrome age 55 and older may have Alzheimer’s disease.

Overall, some 5.3 million in the United States have Alzheimer’s. According to the Alzheimer’s Association that number is expected to increase dramatically as the baby boomer generation continues to age.

Jicha said it’s possible if a patient isn’t right for one of these studies, several more are currently underway that might be a better fit.

“We always have a variety of opportunities,” he said. “Every study has a different number demands.”

“We are trying to build an army to fight Alzheimer’s,” he said. “That army doesn’t just include doctors and researchers but battalions of patients willing to pick up these new weapons to join the fight.”

Fort McMurray Auto Financing Online

Furnasman One Hour UV Lights

Dimebon Online

http://www.dimebonalzheimers.com/

  • Share/Bookmark
Blog Traffic Exchange Related Websites
  • Depression Risk Factors for Women There are a number of ailments that women are actually at risk for developing without actually realizing it. For example, heart disease risk factors for women are much more significant...
  • Alzheimer's Test: When Should You Be Screened? Image via Wikipedia Alzheimer's test: when should you be screened? I was reminded recently of the dangers of Alzheimer's after passing my 54th birthday.  There was an ad with a...
  • Rising Blood Sugar Levels May Cause Brain Damage in Older People Rising blood sugar levels and brain damage in older people may be connected after all, according to new research. Scientists are reporting that rising blood levels may in fact be...
  • Being Fully Present We all have our own reality shaped by our current and past experiences. My perception is as real to me as another's is to them. This is true, but can...
  • French scientists crack secrets of Mona Lisa [/caption] PARIS – The enigmatic smile remains a mystery, but French scientists say they have cracked a few secrets of the "Mona Lisa." French researchers studied seven of the Louvre...
  • Protesters urge peace talks to end Bangkok battles [/caption] BANGKOK – Thailand's Red Shirts offered peace talks Monday to end raging street battles that have killed at least 37 people in Bangkok as a government deadline demanding the...
  • Obama to announce new health benefits [/caption] WASHINGTON – President Barack Obama on Tuesday will announce new health insurance benefits for consumers, marking the first 90 days since he signed landmark legislation to expand coverage. The...

Medivation Reports First Quarter 2010 Financial Results and Provides Corporate Update

Friday, July 9th, 2010

SAN FRANCISCO, May 10 /PRNewswire-FirstCall/ – Medivation, Inc. (Nasdaq: MDVN) today provided a corporate update and reported its financial results for the first quarter ended March 31, 2010.

“After thorough review of all available dimebon data, including the disappointing CONNECTION results, Medivation remains committed to determining whether dimebon may offer clinical benefit to Alzheimer’s and Huntington disease patients,” said David Hung, MD, president and chief executive officer of Medivation.  ”We will continue to enroll patients in the 12-month Phase 3 CONCERT trial in mild-to-moderate Alzheimer’s patients and the six-month Phase 3 HORIZON study in Huntington disease, and will stop our two ongoing Phase 3 trials in moderate-to-severe Alzheimer’s disease.  In reaching this conclusion, we considered all dimebon data generated thus far, including the negative CONNECTION data, the clinical benefit seen in two prior dimebon trials in mild-to-moderate Alzheimer’s disease and Huntington disease, the excellent safety and tolerability profile in all dimebon trials to date covering more than 2,000 patients, the preclinical data consistently showing that dimebon is pharmacologically active, and the potential risks and returns of continuing development for Alzheimer’s and Huntington diseases.  We believe both the CONCERT and HORIZON studies offer independent pathways to registration, and we will be meeting with the Food and Drug Administration this quarter to discuss the CONNECTION data and obtain guidance on our proposed regulatory path forward.”

“We also continue to make progress on our MDV3100 program,” continued Dr. Hung. “This year we and our partner Astellas expect to complete enrollment in the Phase 3 AFFIRM trial in advanced prostate cancer patients and to initiate three new trials in earlier-stage prostate cancer, including a second Phase 3 trial. Our cash position remains strong and, based on current assumptions, we expect our cash to last beyond 2012, without regard to whether Pfizer elects to remain in our dimebon collaboration.  We also expect to have reported top-line data from the CONCERT, HORIZON and AFFIRM trials by the end of 2012.”

Recent Accomplishments and Anticipated Milestones

Dimebon (latrepirdine*)

  • Completed an analysis of data from the Phase 3 CONNECTION trial in patients with mild-to-moderate Alzheimer’s disease, and confirmed that dimebon did not show clinical benefit in this trial. The analysis did not identify any systematic issues with the conduct of the trial or with the drug product that would explain the results.
  • Continued to enroll patients in CONCERT, with the goal of completing patient accrual in 2010. This 12-month randomized, double-blind, placebo-controlled Phase 3 clinical trial in patients with mild-to-moderate Alzheimer’s disease is evaluating the potential efficacy of dimebon when added to ongoing treatment with donepezil.
  • Continued to enroll patients in HORIZON, with the goal of completing patient accrual in 2010. This six-month, randomized, double-blind, placebo-controlled Phase 3 trial is evaluating dimebon’s potential benefits on cognition in patients with Huntington disease.
  • Agreed with our partner Pfizer to discontinue the CONSTELLATION and CONTACT Phase 3 trials in patients with moderate-to-severe Alzheimer’s disease. These trials were part of a label expansion strategy for dimebon, which can be revisited at a later time if the results of the ongoing CONCERT trial warrant.

*Latrepirdine is the proposed generic name for dimebon.

MDV3100

  • Announced publication in The Lancet of positive efficacy data from the Phase 1-2 trial of MDV3100 in advanced prostate cancer patients. MDV3100 demonstrated anti-tumor activity as evaluated by reductions in prostate specific antigen (PSA) levels, radiographic findings and circulating tumor cell (CTC) counts.  MDV3100 was generally well-tolerated in this trial at doses up to and including 240 mg/day.
  • Continued to enroll patients in the AFFIRM trial, with the goal of completing patient accrual in 2010. This randomized, double-blind, placebo-controlled Phase 3 survival trial is evaluating 160 mg/day of MDV3100 in men with castration-resistant prostate cancer who have been previously treated with docetaxel-based chemotherapy.
  • Obtained issuance of a U.S. patent claiming MDV3100′s composition of matter.  The term of this patent runs through 2027, and under current law is eligible for up to five years’ patent term extension based on time spent pursuing regulatory approval to market MDV3100.
  • On track to initiate three new MDV3100 trials in earlier-stage prostate cancer this year: a Phase 3 trial in men with chemotherapy-naive castration-resistant prostate cancer; a Phase 2 head-to-head trial comparing MDV3100 with bicalutamide; and a Phase 1 trial in hormone-naive patients. Initiation of the Phase 3 trial would trigger a $10 million milestone payment under our collaboration agreement with Astellas.

Corporate

  • Implemented a 20 percent workforce reduction to focus resources on the prioritized CONCERT and HORIZON dimebon trials and expanded development of MDV3100.

First Quarter 2010 Financial Results

Revenue for the first quarter of 2010 was $15.7 million, consisting of partial recognition of the non-refundable up-front payments of $225.0 million received from Pfizer in the fourth quarter of 2008 and $110.0 million received from Astellas in the fourth quarter of 2009. Both up-front payments were recorded as deferred revenue upon receipt and are being recognized on a straight-line basis over the estimated performance period of the Company’s obligations under the applicable collaboration agreement, which the Company presently expects to complete in the second quarter of 2013 for the Pfizer collaboration and in the fourth quarter of 2014 for the Astellas collaboration.

For the three months ended March 31, 2010, total operating expenses were $33.4 million, compared with total operating expenses of $22.1 million for the same period in 2009.  These figures include non-cash stock-based compensation expense of $3.5 million in the quarter ended March 31, 2010, compared with $2.6 million for the same period in 2009.

Beginning in October 2008, Pfizer became responsible for 60 percent of all dimebon-related development and commercialization costs in the U.S., and 100 percent of such costs outside the U.S.  Beginning in October 2009, Astellas became responsible for 50 percent of all MDV3100-related development and commercialization costs in the U.S. (other than costs for clinical trials supporting development in both the U.S. and either Europe or Japan, including the ongoing Phase 3 AFFIRM trial and the two additional trials in earlier-stage prostate cancer we expect to initiate in 2010, which are borne two-thirds by Astellas and one-third by Medivation) and 100 percent of such costs outside the U.S.  The parties make quarterly true-up payments as necessary to ensure that each bears its applicable share of costs.  For the first quarter of 2010, the net true-up payments payable to Medivation were $4.6 million and $6.1 million under the Pfizer and Astellas collaborations, respectively.  Medivation presents these cost-sharing true-up payments in the applicable expense line of its consolidated statement of operations.

Medivation reported a net loss for the quarter ended March 31, 2010, of $17.5 million, or $0.51 per share, compared with a net loss of $5.6 million, or $0.19 per share, for the same period in 2009.

Cash, cash equivalents and short-term investments at March 31, 2010, totaled $255.5 million, compared with $278.2 million at December 31, 2009.

2010-12 Financial Outlook

Medivation currently expects that total operating expenses for 2010, net of cost-sharing payments from Pfizer and Astellas, will be between $105 and $115 million.  This forecast includes approximately $13.5 million of non-cash stock-based compensation expense.  We also expect to receive a $10 million milestone payment from Astellas in 2010 upon initiation of the second Phase 3 study of MDV3100.

Medivation believes that its existing cash resources are adequate to fund its currently budgeted operations beyond 2012, without regard to whether Pfizer elects to remain in the dimebon collaboration.  By the end of 2012, the Company expects to have reported top-line data from the CONCERT trial in mild-to-moderate Alzheimer’s disease, the HORIZON trial in Huntington disease, and the AFFIRM trial in castration-resistant prostate cancer patients who have failed chemotherapy.

Conference Call Information

To participate by telephone in today’s live call beginning at 4:30 p.m. Eastern Time, please call 877-303-2523 from the U.S. or +1-253-237-1755 internationally.  In addition, the live conference call is being webcast and can be accessed on the “Events and Presentations” page of the “Investor Relations” section of the Company’s website at www.medivation.com.  A replay also will be available for 30 days following the live call.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options.  Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers.  In September 2008, Medivation announced a global agreement with Pfizer, Inc to develop and commercialize dimebon (latrepirdine) for the treatment of Alzheimer’s and Huntington diseases.  With Pfizer, Medivation is conducting a clinical development program that includes CONCERT, a Phase 3 trial assessing dimebon in patients with mild-to-moderate Alzheimer’s disease, and HORIZON, a Phase 3 trial of dimebon in Huntington disease.  In October 2009, Medivation entered into a global agreement with Astellas Pharma Inc. to develop and commercialize MDV3100 for both early- and late-stage prostate cancer.  The first Phase 3 clinical trial in the MDV3100 development program, known as the AFFIRM trial, is under way in patients with castration-resistant prostate cancer who have previously been treated with docetaxel-based chemotherapy.  Additional trials in earlier-stage prostate cancer will begin in 2010.  For more information, please visit us at www.medivation.com.

Mr Furnaces One Hour

Boonstraonehour

Air Quality’s One Hour

Dimebon Online

http://www.dimebonalzheimers.com/

Auto Transport Montreal  and Car Carrier GTA Ontario

  • Share/Bookmark
Blog Traffic Exchange Related Websites

Job Cuts at Medivation

Friday, June 18th, 2010

Medivation, Inc. (MDVN) recently announced that it intends to reduce its workforce by 20% or 23 people to save costs and focus its resources towards research and developmentmag glass 10x10 Job Cuts at Medivation activities related to dimebon and MDV3100.

Medivation also announced the departure of its senior vice president of clinical development and the vice president of commercial development. The companymag glass 10x10 Job Cuts at Medivation said that it is no longer looking for a new Chief Financial Officer (CFO) as this post will be filled by the current Chief Business Officer (CBO).

Medivation’s workforce reduction announcement comes on the heels of disappointing phase III results reported earlier this month on its lead pipeline candidate, dimebon. Dimebon, which is being developed for Alzheimer’s disease in collaboration with Pfizer, Inc. (PFE), failed to achieve both its primary and secondary endpoints in a phase III study (CONNECTION).

Dimebon was the most advanced pipeline candidate at Medivation, which has no marketed products in its portfolio. The successful development of dimebon would have been a major boost for the company. In addition to the Alzheimer’s indication, Medivation is also studying dimebon for Huntington’s disease.

Going forward, Medivation intends to focus on the further analysis of the CONNECTION data, which will help determine future development plans for the candidate. Dimebon is currently being studied in combination with Pfizer’s Aricept for the treatment of mild-to-moderate Alzheimer’s. Positive results from this study could allow the companies to push for approval of the product as a combination therapy.

Dimebon is also in another study which is being conducted in Huntington disease patients.

We currently have a Neutral recommendation on Medivation. The high profile phase III failure was a major setback for the company. Medivation could suffer another blow if Pfizer decides to pull out from the collaboration agreement for dimebon.

We note that Pfizer already has another Alzheimer’s candidate, bapineuzumab, in its portfolio that is being developed with Elan Corp (ELN) and Johnson & Johnson (JNJ). As such, Pfizer may decide to focus its efforts towards the development of bapineuzumab.

21 Degrees One Hour

Mr Furnaces One Hour

Boonstraonehour

Dimebon Online

http://www.dimebonalzheimers.com/

  • Share/Bookmark
Blog Traffic Exchange Related Websites
  • Intel buys McAfee for $7.7B in push beyond PCs [/caption] SAN FRANCISCO – Talk about a new meaning for "Intel Inside." Intel Corp. wants to be inside your television. And your cell phone. And your car. And pretty much...
  • 3 Things to Know About the Most Valuable Silver Coin The most valuable silver dollar is the 1804 Silver Dollar with the Draped Bust. As a side note, this coin is not only the most valuable in the silver coin...
  • Is Clean Coal Really Clean? Not Really... Dear EarthTalk: As I understand it, “clean” coal really isn’t—yet the Bush Administration gushed strongly for it. What is Obama’s take on it? Barack Obama and George W. Bush differ...
  • Global Warming-How It Could Spark World War III by mandiberg Global Warming-How It Could Spark World War III These Days global warming is a very hot topic and little wonder, seeing as the earth grows hotter with each...
  • Osteoporosis Risk Factors for Women There are a number of ailments that women are actually at risk for developing without actually realizing it. For example, osteoporosis risk factors for women are much more significant than...
  • Google says China partially blocks search service [/caption] BEIJING – A Google search feature was blocked in China on Thursday, the company said as it awaited Beijing's decision on whether to renew its operating license amid tensions...
  • Geron explains stop on stem cell study MENLO PARK, Calif., August 18, 2009 - Geron Corporation announced that its IND (Investigational New Drug application) for GRNOPC1, a cell therapy for neurologically complete, subacute spinal cord injury, has...

Ease Up on Those Carbs and Sugars

Saturday, April 4th, 2009

It has been noted and counted that the average American consumer takes in more than 130 actual pounds of sugar each and every year.  Well that is at present in 2009.  The numbers continue to increase and grow every year.  Yet some are concerned that we have taken almost all fats out of our diet – fats are considered “evil” and more than harmful at best.   Yet the plague of obesity continues to grow – even in third world counties who do not have fast food or a single Mc Donald’s “Golden Arches” restaurant in sight.  Is this plague of obesity a result of our eliminating all fats possible in our diets and replacing intakes with carbohydrates?

Excess sugar can be converted by the body itself into the storage medium, saturated fat and fats, which themselves and be bad for your brain and your heart cardiac system as well.  A high sugar diet can increase free radical activity and damage brain cells, contributing itself to additional and further memory loss.   In addition it has been found sugar also makes our bodies less able to successfully fight off infections in our immune systems which then again are not a good thing by any measure or test.

Diabetes Linked with Alzheimer’s Disease: Patients Who Develop … – New research shows that type 2 diabetes doubles a person’s risk of developing Alzheimer’s disease later in life, making the prevention of diabetes even more significant. … type of diabetes, responsible for over 80% of North American diabetes cases. The blood sugar disturbance has been linked to dozens of different health problems, from vision deterioration to stroke – and the latest research points to a connection between diabetes and later development of Alzheimer’s. …

#1 Health Advice » Blog Archive » How to deal with Alzheimer’s disease – They also had more than twice the amyloid plaque in their brains (a sign of Alzheimer’s) and gained 17 percent more weight than the others. It’s unclear if the sugar or weight gain was more to blame, but cutting back seems like a good …

Diabetes and Alzheimer’s disease linked to each other – A new study finds that diabetes’ destructive impact on blood vessels supplying the brain may begin long before the disease can be detected, just when the body begins having trouble regulating blood sugar. …

Coconut Oil and Alzheimer’s Disease – Dr. Mary Newport recounted a riveting story about her husband who was stricken with Alzheimer’s disease at the young age of 58. Thankfully for us all, Dr. Newport didn’t simply accept that this diagnosis would lead to an inevitable … The researchers found that MCTs preserved brain function during periods of low blood sugar without generating the risk of high blood sugar. This is an important finding because one current theory is that certain forms of brain dysfunction …

 

Dimebon Alzheimer?s Disease

http://www.dimebonalzheimers.com

  • Share/Bookmark
Blog Traffic Exchange Related Websites
  • Alzheimer's Risk:Can the Right Diet Help You Avoid It? Image via Wikipedia Alzheimer's risk: can the right diet help you avoid it? There's a possibility according to a new study which stresses a diet of fish, poultry, dark greens,...
  • Warp Speed Fat Loss: What Is It? First off, Warp Speed Fat Loss is a very cool concept. The idea that you have in your hands the exact step by step rapid weight loss blueprint that can...
  • Diet Round-up #1 If you've been breathing air for any significant time, chances are good you've heard about a few weight-loss diets out there. By definition, a diet is what you eat. If...
  • Acid Alkaline Diet Did you know that there is a connection between the food you eat, the level of acidity in your body and your weight? Until just a couple of years ago,...
  • Almonds… mmmmm…. A hint of sweetness, a little bit of chewiness with a side of crunch. That's how I'd describe the Almond and lately it's been a staple food for me, particularly...
  • Physical Fitness and Mental Health and Wellbeing Are Closely Linked We are all aware of the physical benefits of a structured exercise program. Stronger muscles, joints and bones, better body weight control, protection from disease and a slowing of the...
  • Insulin Resistance - Is it holding you back? Feeling sluggish? Having trouble concentrating? Always irritable? ALWAYS HUNGRY??? To a struggling dieter, these feelings might seem quite ordinary, but for a person carrying around more weight than they should,...